Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans

BACKGROUND: Few adults at high risk for atherosclerotic cardiovascular disease events use a PCSK9i (proprotein convertase subtilisin/kexin type 9 inhibitor). METHODS AND RESULTS: Using data from the US Veterans Health Administration, we identified veterans who initiated a PCSK9i between January 2018...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Heart Assoc
Main Authors: Derington, Catherine G., Colantonio, Lisandro D., Herrick, Jennifer S., Cook, James, King, Jordan B., Rosenson, Robert S., Poudel, Bharat, Monda, Keri L., Navar, Ann Marie, Mues, Katherine E., Stevens, Vanessa W., Nelson, Richard E., Vanneman, Megan E., Muntner, Paul, Bress, Adam P.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8174184/
https://ncbi.nlm.nih.gov/pubmed/33821686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.120.019254
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados